/Dexcom%20Inc%20logo%20on%20sign-by%20Michael%20Vi%20via%20Shutterstock.jpg)
Valued at a market cap of $29.6 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company specializing in designing, developing, and commercializing continuous glucose monitoring (CGM) systems. Its products, including the Dexcom G6 and G7, aim to help people with diabetes manage their blood glucose levels through real-time data transmission and monitoring.
Shares of the medical device company have underperformed the broader market over the past 52 weeks. DXCM has declined 27.9% over this time frame, while the broader S&P 500 Index ($SPX) has gained 30.4%. In 2024, DXCM stock dropped nearly 39%, compared to SPX's 23.1% YTD gain.